HR Pharmaceuticals, Inc. Received Exclusive Commercialization Rights to Poiesis Medical’s Dual Balloon Catheter Technology in North America On December 28, 2023, HR Pharmaceuticals entered into a c...
DNA Sequencing stands as a cornerstone technology, revolutionizing the landscape of biological sciences and the healthcare market outlook. This groundbreaking technology has evolved significantly over the years, transforming from a time-consuming and costly procedure into a high-throughput, efficient, and cost-effe...
Find More
T-cell receptor (TCR)-dependent treatment involves modified immune cells aimed at attacking particular tumor indicators. This treatment approach necessitates a systematic procedure including patient evaluation (e.g., for HLA-A*02:01 and precise tumor markers), collecting immune cells, creating the altered TCR produ...
Find More
Hematopoietic progenitor kinase (HPK1) belongs to the family of Ste20 serine/threonine kinases known as mitogen-activated protein kinase kinase kinase kinase (MAP4K). It is primarily expressed in hematopoietic cells and functions as a negative regulator of T-cell receptor (TCR) and B-cell signaling, serving as an i...
Find More
Savara Introduced aPAP ClearPathTM to detect Autoimmune Pulmonary Alveolar Proteinosis On December 21, 2023, Savara, a clinical stage biopharmaceutical company launched aPAP ClearPathTM, which is used by the physicians to obtain a conclusive diagnosis of Autoimmune Pulmonary Alveolar Proteinosis (aPAP), a ...
Find More
The escalating burden of blood cancer presents a pressing global health concern, with its incidence rising steadily. This surge is attributed to various factors, including an aging population, lifestyle changes, and environmental influences. However, amidst this challenge, advancements in Blood Cancer Diagnostics D...
Find More
Integra LifeSciences to Buy Johnson & Johnson’s Acclarent and its ENT Tech On December 13, 2023, Integra LifeSciences entered into a definitive agreement to acquire Acclarent from Johnson & Johnson MedTech. Acclarent strengthens Integra's position in the ENT treatment market. Acclarent is a component of ...
Find More
Eisai Submits Marketing Authorization Application In Japan for Anticancer Agent Tasurgratinib For Biliary Tract Cancer With FGFR2 Gene Fusion Eisai Co., Ltd. has officially submitted a request for marketing authorization in Japan for tasurgratinib succinate, its internally developed tyrosine kinase inhibitor tar...
Find More
Date of Abstract presentation11th December 2023IndicationsAggressive B-cell lymphoma (a-BCL)Abstract Number4459Abstract typePoster Approximately 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) experience relapse following initial treatment with rituximab, cyclophosphamide, doxorubicin, vincr...
Find More
Date of Abstract presentation9th December 2023IndicationsRelapsed/Refractory (r/r) Large B-Cell and Follicular LymphomasAbstract Number2095Abstract typePoster Despite the rising clinical fascination with autologous CAR T-cell therapies for hematologic malignancies and their noteworthy achievements, persistent ch...
Find More
Celiac disease is an autoimmune disorder against the gluten consumed that creates toxins, thereby, d.....
Find More
Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....
Find More
Cachexia is a complicated metabolic syndrome related to underlying illness and characterized by musc.....
Find More
Healthcare Performance Improvement provides proven methods for sustaining and building a culture of .....
Find More
Hospital-acquired bacterial pneumonia (HABP) is the most common type of health-care-associated infec.....
Find More
Toll-like receptors (TLR) 7 and 8 are functionally localized to endosomes and recognize specific RNA.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
